bioRxivMicrobiology
Engineering a customizable antibacterial T6SS-based platform in Vibrio natriegens
Abstract
Bacterial pathogens are a major risk to human, animal, and plant health. To counteract the spread of antibiotic resistance, alternative antibacterial strategies are urgently needed. Here, we constructed a proof-of-concept customizable, modular, and inducible antibacterial toxin delivery platform. By engineering a type VI secretion system (T6SS) that is controlled by an externally induced on/off switch, we transformed the safe bacterium, Vibrio natriegens, into an effective antibacterial weapon. Furthermore, we demonstrated that the delivered effector repertoire, and thus the toxicity range of this platform, can be easily manipulated and tested. We believe that this platform can serve as a foundation for novel antibacterial bio-treatments, as well as a unique tool to study antibacterial toxins.
- organism: bacteria (other)
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A new family of Type VI secretion system-delivered effector proteins displays ion-selective pore-forming activity
G. Mariano, K. Trunk, … S. J. Coulthurst·bioRxiv·Jun 20, 2019
- Post-phagocytosis activation of NLRP3 inflammasome by two novel T6SS effectors
- A Vibrio T6SS-mediated lethality in a marine animal model
H. Cohen, M. Gerlic, D. Salomon·bioRxiv·Mar 6, 2023
- Collective protection against the type VI secretion system in bacteria
E. T. Granato, W. P. J. Smith, K. R. Foster·bioRxiv·Sep 12, 2022
- A new class of polymorphic T6SS effectors and tethers
K. Kanarek, C. M. Fridman, … D. Salomon·bioRxiv·Oct 27, 2022
- A subcellular biochemical model for T6SS dynamics reveals winning competitive strategies
Y. L. Lin, S. N. Smith, … C. H. Rycroft·bioRxiv·Jul 17, 2021